SOD1 and Alzheimer disease: The median SOD1 levels were significantly increased in the platelets of AD patients by 8% (p = 0.036) and, importantly, showed an early peripheral change during cognitive decline with a 9% (p = 0.003) rise in MCI patients versus controls (Table S4B).